273 related articles for article (PubMed ID: 33987994)
1. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
2. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
4. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.
Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756
[TBL] [Abstract][Full Text] [Related]
8. Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI.
Kim HS; Kwon SL; Choi SH; Hwang I; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
Eur Radiol; 2020 Apr; 30(4):2171-2181. PubMed ID: 31953664
[TBL] [Abstract][Full Text] [Related]
9. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI.
Pak E; Choi KS; Choi SH; Park CK; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Sep; 22(9):1514-1524. PubMed ID: 34269536
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
13. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
15. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
[TBL] [Abstract][Full Text] [Related]
16. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
17. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
19. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
Bauer AH; Erly W; Moser FG; Maya M; Nael K
Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
